GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (NAS:KALV) » Definitions » Debt-to-Equity

KalVista Pharmaceuticals (KalVista Pharmaceuticals) Debt-to-Equity

: 0.08 (As of Jan. 2024)
View and export this data going back to 2015. Start your Free Trial

KalVista Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $1.19 Mil. KalVista Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $6.26 Mil. KalVista Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $88.58 Mil. KalVista Pharmaceuticals's debt to equity for the quarter that ended in Jan. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for KalVista Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

KALV' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.2   Med: 0.02   Max: 0.11
Current: 0.08

During the past 12 years, the highest Debt-to-Equity Ratio of KalVista Pharmaceuticals was 0.11. The lowest was -0.20. And the median was 0.02.

KALV's Debt-to-Equity is ranked better than
63.25% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs KALV: 0.08

KalVista Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for KalVista Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Debt-to-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 0.02 0.04 0.05

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.06 0.07 0.08

Competitive Comparison

For the Biotechnology subindustry, KalVista Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Debt-to-Equity falls into.



KalVista Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

KalVista Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Apr. 2023 is calculated as

KalVista Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KalVista Pharmaceuticals  (NAS:KALV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


KalVista Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals (KalVista Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.
Executives
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Edward P. Feener officer: Chief Scientific Officer ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Thomas Andrew Crockett director, officer: President and CEO BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ
Paul K. Audhya officer: Chief Medical Officer C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Benjamin L Palleiko officer: CFO and Secretary C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139
Christopher Yea officer: Chief Development Officer ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Albert Cha director 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Patrick Treanor director C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Michael David Smith officer: Senior VP, Development C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Andreas Maetzel officer: Senior Vice President Medical 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Nancy Stuart director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Brian Jg Pereira director C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138
Daniel B Soland director 4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Sv Life Sciences Fund Iv (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108